Amgen 2004 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

2000
Kevin W.
Sharer named
chief executive
offi cer
Amgen
acquires Kinetix
Pharmaceuticals,
a Medford,
Massachusetts-
based company
with expertise
in small-molecule
discovery
2001
FDA approves
Kineret®
(anakinra) to
treat the signs
and symptoms
in patients with
rheumatoid
arthritis whose
disease has failed
to respond to
prior treatment
Kevin W.
Sharer becomes
chairman of
the Board of
Directors
Regulators in
the U.S. and
Europe approve
Aranesp®
(darbepoetin
alfa) to
treat anemia
associated
with chronic
kidney failure
2002
Regulators in the
U.S. and Europe
approve Neulasta®
(pegfi lgrastim) to
decrease the inci-
dence of infection
in patients with
non-myeloid
cancers receiving
myelosuppressive
chemotherapy
Regulators in the
U.S. and Europe
approve Aranesp®
for the treatment
of chemotherapy-
induced anemia in
patients with non-
myeloid malignancies
Amgen acquires
Seattle-based Immunex
Corporation
FDA approves
Amgen’s Rhode
Island manufacturing
facility for ENBREL®
FDA approves ENBREL®
to treat the signs and
symptoms of active
arthritis in patients
with psoriatic arthritis
2003
FDA approves
ENBREL® for
the treatment
of ankylosing
spondylitis and
other expanded
indications
1992
– 2004
1999
Gordon
M. Binder
announces
his retirement
as chief
executive
offi cer
FDA approves
Immunex’s
ENBREL®
to treat
patients with
moderately
to severely
active poly-
articular-
course
juvenile
rheumatoid
arthritis
FDA approves
EPOGEN®
to treat
anemia in
children with
chronic renal
failure who
are on dialysis
2004
Regulators in the U.S.,
Canada and Europe approve
Sensipar® (cinacalcet HCl)
for the treatment of secondary
hyperparathyroidism in
chronic kidney disease
patients on dialysis
FDA approves ENBREL®
for the treatment of
chronic moderate to
severe plaque psoriasis
in adults
Amgen expands operations
in Europe to include 10
new Central and Eastern
European countries
Amgen acquires South San
Francisco-based Tularik Inc.
FDA approves Kepivance™
(palifermin) to decrease
the incidence and duration
of severe oral mucositis
(mouth sores) in patients
with hematologic (blood)
cancers undergoing high-
dose chemotherapy, with or
without radiation, followed
by bone marrow transplant
Amgen 2004 Annual Report page 21